Billy Hour

Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension

Manish Saxena, Luke J. Laffin, Claudio Borghi et al. · JAMA · 2025 · 68 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension

Akshay S. Desai, Adam Karns, Jolita Badarienė et al. · JAMA · 2025 · 27 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

POS-109 INTERIM RESULTS OF PHASE 1 AND 2 TRIALS TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND CLINICAL ACTIVITY OF BION-1301 IN PATIENTS WITH IgA NEPHROPATHY

Jonathan Barratt, Billy Hour, Laura Kooienga et al. · Kidney International Reports · 2022 · 15 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +8

FC 040INTERIM RESULTS OF PHASE 1 AND 2 TRIALS TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND CLINICAL ACTIVITY OF BION-1301 IN PATIENTS WITH IGA NEPHROPATHY

Jonathan Barratt, Billy Hour, Cailin Sibley et al. · Nephrology Dialysis Transplantation · 2021 · 14 citations

Life Sciences, Immunology, Nephrology +17

The Global Kidney Patient Trials Network and the CAPTIVATE Platform Clinical Trial Design

Sradha Kotwal, Vlado Perkovic, Meg Jardine et al. · JAMA Network Open · 2024 · 13 citations · Full text

Medicine, Nephrology, Pharmacotherapy +14